Office of Research
Clinical Trials

Leading the Future of Clinical Medicine
The College of Medicine is a hub for groundbreaking clinical research. With over 30 specialized research units, our teams are dedicated to translating laboratory discoveries into life-saving clinical applications. From neurology to oncology, we provide the infrastructure and expertise necessary to push the boundaries of modern medicine.

Browse our Research Units below to view current study listings.

Clinical Trials Search

Aram Zabeti, MD

Aram Zabeti, MD

Multiple Sclerosis

Phase 1

Studying TRX319 Cell Therapy for Progressive Multiple Sclerosis

This research study is testing an investigational cell therapy called TRX319 for adults with primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS). The goal is to learn whether TRX319 is safe and to look for signs that it may help slow or improve disease progression. Participants will receive a single intravenous infusion of TRX319. Some participants may also receive bendamustine before the infusion, depending on the study group. The study includes screening tests, physical examinations, blood tests, MRI scans, spinal fluid testing, and assessments of walking, hand function, vision, and thinking abilities. Participants will be followed for about one year after treatment. Information from this study may help researchers develop new treatment options for people with progressive forms of multiple sclerosis.

Aram Zabeti, MD

Aram Zabeti, MD

Multiple Sclerosis

Phase 3

Studying a Switch in Treatment for Relapsing Multiple Sclerosis

This study is testing whether a daily oral medicine called remibrutinib works as well as the current treatment, ocrelizumab, for people with relapsing multiple sclerosis. People who have been on ocrelizumab for at least 18 months and are between 40 and 70 years old may join. The study will look at how MS changes over time using MRI scans, physical tests, and symptom reports. Participants may receive remibrutinib or continue ocrelizumab for up to two years, and those who finish this part may continue on remibrutinib for another two years. The study aims to learn whether switching to remibrutinib is safe, effective, and easier for patients.

Lawrence Goldstick, MD

Lawrence Goldstick, MD

Multiple Sclerosis

Phase 3

Remibrutinib in SPMS Study

This is a Phase III randomized, double-blind, placebo-controlled study testing remibrutinib in adults with secondary progressive multiple sclerosis (SPMS). About 1,275 eligible participants will be randomly assigned to take remibrutinib or a matching placebo. The main goal is to find out whether remibrutinib can slow confirmed worsening of disability over time, measured mainly by a standard disability scale (EDSS) over an event-driven period of up to about five years. The study will also track shorter-term disability changes, walking and hand function, cognitive speed, MRI measures (new or enlarging lesions and brain volume loss), and safety events. After the double-blind core part, participants may join an open-label extension where they can receive remibrutinib. Screening and regular assessment visits will include exams, MRI scans, safety lab tests, and functional tests.

Learn More about Remibrutinib in SPMS Study
Lawrence Goldstick, MD

Lawrence Goldstick, MD

Multiple Sclerosis

Phase 3

Frexalimab Versus Teriflunomide in MS

This is a pair of Phase 3, randomized, double-blind studies comparing an investigational antibody called frexalimab to the approved oral drug teriflunomide in adults with relapsing multiple sclerosis (ages 18-55). Each study measures how often participants have relapses over the study period (annualized relapse rate) and follows safety, disability changes, MRI lesion counts, brain volume, cognitive tests, and blood markers. The studies are event-driven: every participant will be treated at least 12 months, and many will be followed up to about 156 weeks (three years). Visits are every 4 weeks for the first 6 months, then every 3 months, with an end-of-study visit and three follow-up visits. Safety monitoring includes tracking adverse events, lab tests, ECGs, and antibodies to the drug. The goal is to see if frexalimab reduces relapses and is safe compared with teriflunomide.

Learn More about Frexalimab Versus Teriflunomide in MS
Lawrence Goldstick, MD

Lawrence Goldstick, MD

Multiple Sclerosis

Phase 3

Ublituximab Modified Regimen Study

This Phase 3b study tests a changed dosing plan of ublituximab, a medicine that targets B cells, in people with relapsing multiple sclerosis (RMS). The study has three parts: Part A is open to eligible participants and looks at MRI brain lesions over about 48 weeks; Part B is randomized and double-blind to study drug levels and compare to placebo up to 16 weeks; Part C enrolls people who had a suboptimal experience on another anti-CD20 treatment to see how they do on ublituximab. Main goals are to see if the modified schedule prevents new gadolinium-enhancing MRI lesions and to understand the drug's blood levels. Participants have regular visits for dosing, safety checks, and MRI scans. People with active infections, certain immune diseases, prior serious infusion reactions to anti-CD20 drugs, some prior cancer or prior use of specific immunosuppressive drugs are not allowed to join.

Learn More about Ublituximab Modified Regimen Study
Aram Zabeti, MD

Aram Zabeti, MD

Multiple Sclerosis

Stem Cell Transplant V/S BAT Therapy

This is a Randomized study to compare the efficacy, safety, immunologic effects, and cost-effectiveness of myeloablative and immunoablative therapy followed by autologous hematopoietic stem cell transplant (AHSCT) versus best available therapy (BAT) over 72 months in participants with relapsing MS and continued MS disease activity despite treatment with DMTs.

Learn More about Stem Cell Transplant V/S BAT Therapy
Aram Zabeti, MD

Aram Zabeti, MD

Multiple Sclerosis

Phase 4

Early Intensive v/s Escalation Tx

This is an open-label, rater unblinded, randomized clinical trial. Participants will be randomized in a 1:1 ratio to an EHT approach as first-line (alemtuzumab, natalizumab, rituximab, ocrelizumab, or ofatumumab at clinician and participant discretion), or escalation approach (any approved DMT except alemtuzumab, natalizumab, rituximab, ocrelizumab, or ofatumumab as first-line with or without subsequent escalation to any approved DMT).

Learn More about Early Intensive v/s Escalation Tx
513-907-6459